References
- Bag A, Rawat S, Pant NK, et al (2012). Cancer patterns in Nainital and adjoining districts of Uttarakhand: A one year survey. J Nat Sci Biol Med, 3, 186-8. https://doi.org/10.4103/0976-9668.101911
- Bag A, Upadhyay S, Jeena LM, Pundir P, Jyala NS (2013). GSTT1 null genotype distribution in the Kumaun region of northern India. Asian Pac J Cancer Prev, 14, 87-9. https://doi.org/10.7314/APJCP.2013.14.1.87
- Barahmani N, Carpentieri S, Li XN, et al (2009). Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol, 11, 292-300. https://doi.org/10.1215/15228517-2008-089
- Cheng CF, Juan SH, Chen JJ, et al (2008). Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis, 13, 883-94. https://doi.org/10.1007/s10495-008-0214-9
- Di Pietro G, Magno LAV, Rios-Santos F (2010) Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol, 6, 153-70. https://doi.org/10.1517/17425250903427980
- Donnelly JG (2004). Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit, 26, 231-5. https://doi.org/10.1097/00007691-200404000-00026
- Erculj N, Kovac V, Hmeljak J, Dolzan V (2012). The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol, 23, 961-7. https://doi.org/10.1093/annonc/mdr324
- Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600. https://doi.org/10.3109/10409239509083491
- He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009). A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat, 113, 585-94. https://doi.org/10.1007/s10549-008-9962-z
- Husain K, Whitworth C, Somani SM, Rybak LP (2001). Carboplatin-induced oxidative stress in rat cochlea. Hear Res, 159, 14-22. https://doi.org/10.1016/S0378-5955(01)00306-9
- Klebanoff SJ (1999). Myeloperoxidase. Proc Assoc Am Physicians, 111, 383-9.
- Lin H, Sue YM, Chou Y, et al (2010). Activation of a nuclear factor of activated T-lymphocyte-3 (NFAT3) by oxidative stress in carboplatin-mediated renal apoptosis. Br J Pharmacol, 161, 1661-76. https://doi.org/10.1111/j.1476-5381.2010.00989.x
- Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev, 63, 437-59. https://doi.org/10.1124/pr.110.003533
- Marsh S, Paul J, King CR, et al (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol, 25, 4528-35. https://doi.org/10.1200/JCO.2006.10.4752
- Millward MJ, Boyer MJ, Lehnert M, et al (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol, 14, 449-54. https://doi.org/10.1093/annonc/mdg118
- Moyer AM, Sun Z, Batzler AJ, et al (2010). Glutathione pathway genetic polymorphisms and lung cancer survival after platinum- based chemotherapy. Cancer Epidemiol Biomarkers Prev, 19, 811-21. https://doi.org/10.1158/1055-9965.EPI-09-0871
- Nakamura Y (2008). Pharmacogenomics and Drug Toxicity. N Engl J Med, 359, 856-8. https://doi.org/10.1056/NEJMe0805136
- O?dwyer PJ, Johnson SW, Hamilton TC (1997). Cisplatin and its analogues. In 'Cancer: Principles and Practices of oncology', Eds DeVita VT Jr., Hellman S, Rosenberg SA. Lippincott-Raven, Phila, 418-32.
- Ochoa L, Waypa G, Mahoney JR Jr, Rodriguez L, Minnear FL (1997). Contrasting effects of hypochlorous acid and hydrogen peroxide on endothelial permeability: prevention with cAMP drugs. Am J Respir Crit Care Med, 156, 1247-55. https://doi.org/10.1164/ajrccm.156.4.96-10115
- Palma JP, Aggarwal SK (1994). Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro. Anticancer Drugs, 5, 615-22. https://doi.org/10.1097/00001813-199412000-00002
- Piedrafita FJ, Molander RB, Vansant G, et al (1996). An Alu element in the myeloperoxidase promoter contains a composite SP1- thyroid hormone-retinoic acid response element. J Biol Chem, 271, 14412-20. https://doi.org/10.1074/jbc.271.24.14412
- Sambrook J, Fritsch E, Maniatis T (1989). Molecular cloning- a laboratory manual. Cold Spring Harbor Laboratory Press, NY, 1989.
- Soo RA, Kawaguchi T, Loh M, et al (2012). Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncol, 8, 451-62. https://doi.org/10.2217/fon.12.25
- Thorn CF, Ji Y, Weinshilboum RM, Altman RB, Klein TE (2012). PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenet Genomics, 22, 646-51. https://doi.org/10.1097/FPC.0b013e3283527c02
- Undevia SD, Gomez-Abuin G, Ratain MJ (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer, 5, 447-58. https://doi.org/10.1038/nrc1629
Cited by
- Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7277